Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011:2011:453179.
doi: 10.1155/2011/453179. Epub 2011 Jul 4.

Erythropoietin: recent developments in the treatment of spinal cord injury

Stephana Carelli  1 , Giovanni Marfia, Anna Maria Di Giulio, Giorgio Ghilardi, Alfredo Gorio
Affiliations

Erythropoietin: recent developments in the treatment of spinal cord injury

Stephana Carelli et al. Neurol Res Int. 2011.

Abstract

Erythropoietin (EPO), originally identified for its critical function in regulating production and survival of erythrocytes, is a member of the type 1 cytokine superfamily. Recent studies have shown that EPO has cytoprotective effects in a wide variety of cells and tissues. Here is presented the analysis of EPO effects on spinal cord injury (SCI), considering both animal experiments concerning to mechanisms of neurodegeneration in SCI and EPO as a neuroprotective agent, and some evidences coming from ongoing clinical trials. The evidences underling that EPO could be a promising therapeutic agent in a variety of neurological insults, including trauma, are mounting. In particular, it is highlighted that administration of EPO or other recently generated EPO analogues such as asialo-EPO and carbamylated-EPO demonstrate interesting preclinical and clinical characteristics, rendering the evaluation of these tissue-protective agents imperative in human clinical trials. Moreover the demonstration of rhEPO and its analogues' broad neuroprotective effects in animal models of cord lesion and in human trial like stroke, should encourage scientists and clinicians to design clinical trials assessing the efficacy of these pharmacological compounds on SCI.

PubMed Disclaimer

References

    1. Tator CH. Update on the pathophysiology and pathology of acute spinal cord injury. Brain Pathology. 1995;5(4):407–413. - PubMed
    1. Norenberg MD, Smith J, Marcillo A. The pathology of human spinal cord injury: defining the problems. Journal of Neurotrauma. 2004;21(4):429–440. - PubMed
    1. American Association of Neurological Surgeons. Pharmacological therapy after acute cervical spinal cord injury. Neurosurgery. 2002;50(3):S63–S72. - PubMed
    1. Brines M, Cerami A. Erythropoietin and the Nervous System: Novel Therapeutic Options for Neuroprotection. New York, NY, USA: Springer; 2006. Erythropoietin in spinal cord injury; pp. 147–164.
    1. Carnot C, DeFlandre C. Sur l'activite hematopoietique du serum au cours de la regeneration due sang. Comptes Rendue Hebdomadaires des Séances de Paris. 1906;143:432–435.